ClinicalTrials.gg
RecruitingNCT05419895Updated Jun 10, 2026

Early Diagnostic Response Model (EDRM)

An interventional study of Early Diagnostic Response Model (EDRM) in Autism Spectrum Disorder and Autism, sponsored by Emory University. Recruiting at 1 site in United States. Open to participants aged 16 Months to 36 Months. Per ClinicalTrials.gov, last updated 2026-06-10.

Primary conditionAutistic DisorderRegistry: Autism Spectrum DisorderReclassifiedWhy we changed it
Registry
Autism Spectrum Disorder — the first condition term the registry derived for this study.
ClinicalTrials.gg
Autistic Disorder
Why
  1. The study's listed conditions name Autistic Disorder, a narrower term within Autism Spectrum Disorder.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Emory University · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
16 Months to 36 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Autistic Disorder by Emory University — 5 open to participants now, 5 under way, none of them phase 3. Autistic Disorder · Emory University.

Started
2022
the only one that year
No phase
8 of 10
4 open now
Registered
6th of 10
by date

Among the 10 studies in Autistic Disorder by Emory University, this one is the only one that started in 2022, is one of 8 with no phase, and was the 6th registered.

Autistic Disorder

1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

5 of the 10 studies in Autistic Disorder by Emory University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 184 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 144 (78%) stop at 75 or younger; 150 take children under 18; 56 take healthy volunteers.

This study: 16 Months to 36 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Autistic Disorder by Emory University, or all of them as a file.
02

Study summary

Babies Can't Wait (BCW) in Georgia will be referring families with children seeking an autism spectrum disorder (autism) diagnosis at the Emory Autism Center's (EAC) Child Screening and Assessment Clinic.The objective of this study is to develop, pilot, and evaluate a diagnostic protocol for children identified at high risk for autism in the BCW early intervention program screening (part of a public health service). This program evaluation will be using pre- and post-data and data collected through the process to evaluate the effectiveness of the EDRM pilot.

Read the detailed description

The objective of this study is to develop, pilot, and evaluate a diagnostic protocol to assess high-risk toddlers for autism spectrum disorder (ASD) diagnosis of families enrolled in the Georgia Babies Can't Wait (BCW) early intervention program. The Early Diagnostic Response Model (EDRM) project will be addressing children who are identified at high risk for ASD according to the BCW screening protocol, which is the M-CHAT-R/F. Community psychologist will be taught the protocol and receive referrals to build capacity and better address the need across the state. Currently, many children who are screening high-risk for ASD in BCW districts are unable to access follow-up evaluations due to limited community resources and long wait times. It is hypothesized that the EDRM will be successful in increasing the number of BCW families that access an ASD evaluation using telehealth tools and testing protocols and that the families and clinicians involved will be satisfied with the streamlined process. The clinicians' conclusions from the EDRM assessment will be based on the Diagnostic and Statistical Manual, 5th edition (DSM-5; American Psychiatric Association [APA], 2013) and are hypothesized to be able to provide high-risk children and their families with the same access to services as an in-person assessment.

A secondary objective is to investigate how many high-risk referral assessments can be completed entirely via streamlined telehealth protocol and how many required additional information to be collected to make a final DSM-5 conclusion.

A tertiary objective is to investigate the improvement of the EDRM as an early identification model to assess for ASD by comparing the numbers of families screened high risk for ASD and referred for an evaluation prior to the study to the number of families who received ASD evaluation by the end of the study through the pilot versus other means. These numbers will be analyzed globally as well as by specific BCW district and other child factors.

03

Conditions studied

  • Autism Spectrum Disorder
  • Autism

Browse trials for

Keywords

  • Autism
  • Early Intervention
  • Telehealth
  • Assessment
04

In context

Autistic Disorder Reclassified

1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

This study's planned enrollment of 300 is above the median of 50 across 814 interventional studies indexed under Autistic Disorder.

Browse Autistic Disorder studies →

Lead sponsor

Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.

Of its 238 completed or terminated interventional studies of FDA-regulated products, 179 (75%) have results posted.

Compared within Autistic Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autism Spectrum Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
16 Months to 36 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All families of children between the ages of 16-30 months of age who scored ≥8 on the MCHAT-R and whose BCW provider refers the child to our clinic by 33 months of age will be a possible participant. Evaluations will be done by 36 months of age.
  • Referring BCW provider must be one of the participating BCW health districts in this pilot study.
  • Parent/Guardian needs to have basic English proficiency
  • Parent/Guardian needs to have internet access
  • Child must have exposure to English either at home or in out-of-home care (e.g., childcare setting).
  • Documentation of M-CHAT-R High-Risk failed score (≥ 8) must be documented in referral.

Exclusion criteria

Exclusion Criteria:

  • Families making self-referrals to the EAC or referrals outside of the targeted BCW districts will be excluded from recruitment for this study.
  • Children above the age of 33 months at the time of the referral will be excluded as the current EDRM protocol has not been developed in this phase of piloting for individuals over this age.
  • Non-English speakers will be excluded from participation due to the current protocol not being applicable to their needs as well as a high correlation between verbal language abilities and social communication and social interaction (SCI) abilities as part of the autism criteria.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

06

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Families with children enrolled in BCW with suspected diagnosis of autism

    Post-consent, families with children between 16-33 months will receive a link to complete the EAC Developmental History Survey on REDCap and a link to complete parent/caregiver questionnaires about developmental and/or adaptive information. Then, the family will be assigned to a clinician for the autism assessment and scheduled their assessment and feedback session (one week later).

    Behavioral: Early Diagnostic Response Model (EDRM)

Interventions

  • BehavioralEarly Diagnostic Response Model (EDRM)

    Use of telehealth capabilities to implement measures and capture and code information related to an autism diagnosis. This program evaluation will be using pre- and post-data and data collected through the process to evaluate the effectiveness of the EDRM pilot.

07

What researchers measure

Primary outcomes

  1. Number of participants referred to the Early Diagnostic Response Model (EDRM)

    Monthly numbers of high-risk referrals to the EDRM pilot project and total number of referrals made to the EDRM at the end of the study

    Time frame: Until the end of the study (approximately one year)

  2. Number of participants consented in the Early Diagnostic Response Model (EDRM) study

    Monthly number of families referred who consent to EDRM participation

    Time frame: Monthly until until the end of the study (approximately one year)

  3. Response rate in the Early Diagnostic Response Model (EDRM) study

    Response rate will be calculated at project end using the formula \[# of families who consented / # of families referred to project\] x 100 = response rate)

    Time frame: Until end of the study (approximately one year)

  4. Number of participants that completed the Early Diagnostic Response Model (EDRM) study

    Quarterly numbers of participants that completed the EDRM assessment protocol and total number of participants who completed EDRM assessment protocol at study conclusion

    Time frame: Every 3 months (Quarterly) until end of study (approximately one year)

  5. Time from referral to completion of the program

    Individual calculation of time from BCW referral to final summary report sent to family using the formula: Date of Final Report sent to family - Date of referral from BCW =Time in EDRM pilot

    Time frame: Up to 12 weeks post-intervention

Secondary outcomes

  1. Number of high-risk referral assessments that completed entirely via streamlined telehealth protocol

    Number of high-risk referral assessments that completed entirely via streamlined telehealth protocol, analyzed globally. Monthly, Quarterly, and Total numbers of participants who completed EDRM pilot assessment.

    Time frame: Every 3 months (Quarterly) until end of study (approximately one year), Up to 12 weeks post-intervention

  2. Number of of high-risk referral by BCW district

    Number of high-risk referral assessments by specific BCW district. Monthly, Quarterly, and Total numbers of participants who completed EDRM pilot assessment.

    Time frame: Every 3 months (Quarterly) until end of study (approximately one year), Up to 12 weeks post-intervention

  3. Number of of high-risk referral by child factors

    Number of high-risk referral assessments by child factors. Monthly, Quarterly, and Total numbers of participants who completed EDRM pilot assessment.

    Time frame: Every 3 months (Quarterly) until end of study (approximately one year), Up to 12 weeks post-intervention

  4. Number of of high-risk referral by clinician setting

    Number of high-risk referral assessments by clinician setting. Monthly, Quarterly, and Total numbers of participants who completed EDRM pilot assessment.

    Time frame: Every 3 months (Quarterly) until end of study (approximately one year), Up to 12 weeks post-intervention

  5. Number of participants with additional information collected to make a final DSM-5 conclusion

    Number of participants with additional information collected to make a final DSM-5 conclusion

    Time frame: Every 3 months (Quarterly) until end of study (approximately one year), Up to 12 weeks post-intervention

  6. Parent satisfaction of EDRM assessment survey

    Administered at the end of individual EDRM assessment. Satisfaction surveys will use a Likert-scale of 1-5 with 1 being strongly disagree and 5 being strongly agree as well as 0 being not applicable/unknown. Higher scores indicate more satisfaction with specific aspect of EDRM project. Total score: 0 to 110.

    Time frame: At completion of EDRM assessment (4 weeks post-intervention)

  7. BCW provider(s) Service Coordinator satisfaction with EDRM assessment survey

    Administered at end of individual EDRM assessment. Satisfaction surveys will use a Likert-scale of 1-5 with 1 being strongly disagree and 5 being strongly agree as well as 0 being not applicable/unknown. Higher scores indicate more satisfaction with specific aspect of EDRM project. Total score: 0 to 110.

    Time frame: At completion of EDRM assessment (4 weeks post-intervention)

  8. Parent satisfaction with access to treatment survey

    Administered 3-months after completion of EDRM assessment. Satisfaction surveys will use a Likert-scale of 1-5 with 1 being strongly disagree and 5 being strongly agree as well as 0 being not applicable/unknown. Higher scores indicate more satisfaction with specific aspect of EDRM project. Total score: 0 to 15.

    Time frame: 3 months after completion of EDRM assessment

  9. BCW provider(s) Early Intervention Coordinator satisfaction with EDRM pilot survey

    Completed every 3 months (Quarterly). Satisfaction surveys will use a Likert-scale of 1-5 with 1 being strongly disagree and 5 being strongly agree as well as 0 being not applicable/unknown. Higher scores indicate more satisfaction with specific aspect of EDRM project. Total score: 0 to 55

    Time frame: Every 3 months (Quarterly) until end of study (approximately one year), Up to 12 weeks postintervention

  10. Number of families screened high risk for ASD and referred for an evaluation

    Number of families screened high risk for ASD and referred for an evaluation

    Time frame: Through study completion, an average of 1 year

  11. Number of families who received ASD evaluation by the end of the study through the pilot versus other means

    Number of families who received ASD evaluation by the end of the study through the pilot versus other means

    Time frame: Through study completion, an average of 1 year

08

Study locations

1 of 1 sites recruiting
  • Emory Autism Center
    Atlanta, Georgia 30322, United States
    Recruiting
09

References and documents

Individual participant data

Plan to share: Yes — All individual participant data collected during the EDRM pilot will be shared, after de-identification process has been completed. Proposals may be submitted to up to 3 years following article publication. After 3 years, data will be provided in Emory University's data warehouse but without investigator support other than deposited materials.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: After completion of the EDRM pilot project; Beginning 3 months and ending within 3 years of published results through peer-review process.

Access criteria: Researchers who provide a methodologically sound proposal that has been approved by an IRB. To achieve aims in proposed activity and/or for meta-analysis of telehealth assessments

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Jul 2028, 73 months after the start.

Of 355 non-industry interventional studies with no phase under Autistic Disorder, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 73 months is above that.

Counting every sponsor, half of 367 studies reached it within 26 months; a quarter within 13 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2022
First posted
Jun 15, 2022
StartActual
Jun 16, 2022
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05419895
Lead sponsor
Emory University
Collaborators
Georgia Department of Public Health
Responsible party
Allison Schwartz (Assistant Professor, Emory University) — Principal investigator
First posted
Jun 15, 2022
Start date
Jun 16, 2022
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Jun 10, 2026

Study contacts

Allison Schwartz, PhD
Contact
allison.schwartz@emory.edu
404.727.8350
Allison Schwartz, PhD
principal investigator · Emory University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion